Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.
We cannot recommend reimbursement of Ipilimumab at the submitted price.
Reimbursement not Recommended
Following review, we recommend reimbursement of vernakalant in the hospital setting.
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland
Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.
We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.